Advertisement
UK markets close in 2 hours 26 minutes
  • FTSE 100

    7,720.31
    -2.24 (-0.03%)
     
  • FTSE 250

    19,389.50
    -97.03 (-0.50%)
     
  • AIM

    735.07
    -1.56 (-0.21%)
     
  • GBP/EUR

    1.1697
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2699
    -0.0030 (-0.23%)
     
  • Bitcoin GBP

    49,845.75
    -3,192.19 (-6.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,140.56
    -8.86 (-0.17%)
     
  • DOW

    38,875.42
    +84.99 (+0.22%)
     
  • CRUDE OIL

    82.98
    +0.26 (+0.31%)
     
  • GOLD FUTURES

    2,155.10
    -9.20 (-0.43%)
     
  • NIKKEI 225

    40,003.60
    +263.20 (+0.66%)
     
  • HANG SENG

    16,529.48
    -207.62 (-1.24%)
     
  • DAX

    17,950.14
    +17.46 (+0.10%)
     
  • CAC 40

    8,186.27
    +38.13 (+0.47%)
     

ALXN vs. TECH: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alexion Pharmaceuticals (ALXN) and Techne (TECH). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, both Alexion Pharmaceuticals and Techne are sporting a Zacks Rank of # 2 (Buy). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one factor that value investors are interested in.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

ADVERTISEMENT

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

ALXN currently has a forward P/E ratio of 13.14, while TECH has a forward P/E of 60.36. We also note that ALXN has a PEG ratio of 0.88. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. TECH currently has a PEG ratio of 2.87.

Another notable valuation metric for ALXN is its P/B ratio of 3.24. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, TECH has a P/B of 11.73.

These metrics, and several others, help ALXN earn a Value grade of B, while TECH has been given a Value grade of D.

Both ALXN and TECH are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALXN is the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
BioTechne Corp (TECH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research